CN1307993C - 含有大环内酯的药物组合物 - Google Patents

含有大环内酯的药物组合物 Download PDF

Info

Publication number
CN1307993C
CN1307993C CNB028211588A CN02821158A CN1307993C CN 1307993 C CN1307993 C CN 1307993C CN B028211588 A CNB028211588 A CN B028211588A CN 02821158 A CN02821158 A CN 02821158A CN 1307993 C CN1307993 C CN 1307993C
Authority
CN
China
Prior art keywords
formula
compound
amino
propanediol
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028211588A
Other languages
English (en)
Chinese (zh)
Other versions
CN1575173A (zh
Inventor
J·G·迈因加斯内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0127341A external-priority patent/GB0127341D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1575173A publication Critical patent/CN1575173A/zh
Application granted granted Critical
Publication of CN1307993C publication Critical patent/CN1307993C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CNB028211588A 2001-10-23 2002-10-22 含有大环内酯的药物组合物 Expired - Fee Related CN1307993C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0125443.2A GB0125443D0 (en) 2001-10-23 2001-10-23 Organic Compounds
GB0125443.2 2001-10-23
GB0127341.6 2001-11-14
GB0127341A GB0127341D0 (en) 2001-11-14 2001-11-14 Organic compounds

Publications (2)

Publication Number Publication Date
CN1575173A CN1575173A (zh) 2005-02-02
CN1307993C true CN1307993C (zh) 2007-04-04

Family

ID=26246689

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028211588A Expired - Fee Related CN1307993C (zh) 2001-10-23 2002-10-22 含有大环内酯的药物组合物

Country Status (19)

Country Link
US (1) US7259170B2 (enExample)
EP (1) EP1439838A1 (enExample)
JP (1) JP2005509634A (enExample)
KR (2) KR20090114483A (enExample)
CN (1) CN1307993C (enExample)
AU (1) AU2002346859C1 (enExample)
BR (1) BR0213463A (enExample)
CA (1) CA2458690C (enExample)
EC (1) ECSP045086A (enExample)
GB (1) GB0125443D0 (enExample)
HU (1) HUP0402108A3 (enExample)
IL (1) IL160973A0 (enExample)
MX (1) MXPA04003738A (enExample)
NO (1) NO20042074L (enExample)
NZ (1) NZ532412A (enExample)
PL (1) PL368533A1 (enExample)
RU (1) RU2321402C2 (enExample)
WO (1) WO2003035068A1 (enExample)
ZA (1) ZA200401711B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512946A (ja) * 2001-05-09 2005-05-12 ノバルティス アクチエンゲゼルシャフト 選択的免疫調節法
MXPA04006709A (es) 2002-01-11 2004-10-04 Sankyo Co Derivados de aminoalcohol o derivados de acido fosfonico y composiciones farmaceuticas que los contienen.
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
KR20110136901A (ko) 2004-02-24 2011-12-21 상꾜 가부시키가이샤 아미노 알코올 화합물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912238A (en) * 1989-11-09 1999-06-15 Novartis Ag Heteroatoms-containing tricyclic compounds
CN1237906A (zh) * 1996-11-19 1999-12-08 诺瓦提斯公司 1,3－丙二醇衍生物的新用途
CN1261365A (zh) * 1997-06-30 2000-07-26 诺瓦提斯公司 结晶性大环内酯及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68921934T2 (de) 1988-06-29 1995-10-19 Merck & Co Inc Immunsuppressives Agens.
ATE126803T1 (de) * 1989-11-09 1995-09-15 Sandoz Ag Heteroatome enthaltende tricyclische verbindungen.
GB2252041A (en) * 1991-01-23 1992-07-29 Fujisawa Pharmaceutical Co Use of macrolide compounds in treatment of autoimmune myocarditis
AU664178B2 (en) * 1991-03-19 1995-11-09 Vithal J. Rajadhyaksha Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
GB9203636D0 (en) * 1992-02-19 1992-04-08 Lucas Ind Plc Fuel pumping apparatus
KR0155015B1 (ko) * 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
WO1994021642A1 (en) 1993-03-17 1994-09-29 Abbott Laboratories Macrocyclic amide and urea immunomodulators
US5590460A (en) * 1994-07-19 1997-01-07 Tessera, Inc. Method of making multilayer circuit
DE69524962T4 (de) 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
GB9521322D0 (en) 1995-10-17 1995-12-20 Sandoz Ltd Organic compounds
JPH11209277A (ja) 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
ES2240868T3 (es) * 1997-04-04 2005-10-16 Mitsubishi Pharma Corporation Compuesto de 2-aminopropano -1,3-diol, su uso farmaceutico e intermedios en su sintesis.
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
GB0003932D0 (en) 2000-02-18 2000-04-12 Novartis Ag Pharmaceutical compositions
JP2004523275A (ja) 2000-12-22 2004-08-05 アバンテク バスキュラー コーポレーション 治療能力のある薬剤の送達

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912238A (en) * 1989-11-09 1999-06-15 Novartis Ag Heteroatoms-containing tricyclic compounds
CN1237906A (zh) * 1996-11-19 1999-12-08 诺瓦提斯公司 1,3－丙二醇衍生物的新用途
CN1261365A (zh) * 1997-06-30 2000-07-26 诺瓦提斯公司 结晶性大环内酯及其制备方法

Also Published As

Publication number Publication date
MXPA04003738A (es) 2004-07-23
RU2321402C2 (ru) 2008-04-10
AU2002346859B2 (en) 2006-03-02
KR20090114483A (ko) 2009-11-03
CN1575173A (zh) 2005-02-02
HUP0402108A2 (hu) 2005-02-28
WO2003035068A1 (en) 2003-05-01
ECSP045086A (es) 2004-06-28
US7259170B2 (en) 2007-08-21
KR20040052250A (ko) 2004-06-22
CA2458690C (en) 2011-01-25
KR100978971B1 (ko) 2010-08-30
NZ532412A (en) 2006-01-27
AU2002346859C1 (en) 2008-07-10
PL368533A1 (en) 2005-04-04
ZA200401711B (en) 2004-10-21
CA2458690A1 (en) 2003-05-01
RU2004116067A (ru) 2005-04-20
NO20042074L (no) 2004-05-19
IL160973A0 (en) 2004-08-31
EP1439838A1 (en) 2004-07-28
HUP0402108A3 (en) 2008-02-28
BR0213463A (pt) 2004-11-09
US20040192716A1 (en) 2004-09-30
JP2005509634A (ja) 2005-04-14
GB0125443D0 (en) 2001-12-12

Similar Documents

Publication Publication Date Title
RU2490272C2 (ru) Макроциклические ингибиторы серинпротеазы
CN1082371C (zh) 用于治疗呕吐的nk－1受体拮抗剂和5ht3受体拮抗剂
JP6077265B2 (ja) 自己免疫性疾患の処置剤
US20130253071A1 (en) Methods and Compositions for Prevention and Treatment of Inflammatory Disease, Autoimmune Disease and Transplant Rejection
CN1708293A (zh) 治疗脱髓鞘疾病的鞘氨醇－1－磷酸受体激动剂
HK1039072A1 (zh) 佐剂组合物及其使用方法
KR20030070092A (ko) 죽상경화증을 예방 및 치료하기 위한 플라크 관련 분자를함유하는 조성물 및 이 분자를 이용하는 방법
JPWO2000009127A1 (ja) 多発性硬化症治療薬
CN1304315A (zh) 环孢菌素类化合物在治疗炎症性自身免疫疾病中的用途
JP2025156396A (ja) 移植片対宿主病の予防におけるｈｄｌの使用
CN1103782A (zh) 眼局部给药的抗变态反应的药物组合物
CN101043883A (zh) (z)－2－氰基－3－羟基－丁－2－烯酸－(4'－三氟甲基苯基)－酰胺用于治疗炎症性肠病的用途
CN1575173A (zh) 含有大环内酯的药物组合物
RU2369609C2 (ru) Алкилзамещенные индолхиноксалины
CN1181818C (zh) 治疗原虫感染的方法
CN1146430C (zh) 用穗霉素或其衍生物减轻或防止疼痛的方法
AU2002346859A1 (en) Macrolides containing pharmaceutical compositions
EP2328571B1 (en) Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies
JP2010536827A (ja) ある種の炎症性障害の治療に有用なカルボニルアミノ誘導体
CN1051706C (zh) 氨基氢化喹唑啉类化合物及其衍生物戒降药物依赖性的新用途
US20240197816A1 (en) Composition and method for prolong survival of transplant and recipient
JP2005509634A5 (enExample)
CN1276721A (zh) 适于制备治疗炎症和/或自身免疫性疾病的药物组合物的6,7－取代的2－氨基－1,2,3,4－四氨化萘的用途
CN1703234A (zh) 低分子量凝血酶抑制剂的新用途
CN1204962A (zh) 含2,2'－二－1h－吡咯化合物的协同免疫抑制组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070404

Termination date: 20131022